As preventable causes continue to take too many lives in some of the most vulnerable parts of the world, international organizations have teamed up to launch innovative efforts to combat this problem. Malaria in pregnancy is a health risk for both mother and fetus, and determining the precise drug regimen for pregnancy in malarious areas is an ongoing challenge.
One of these initiatives, known as “Transforming IPT for Optimal Pregnancy” (TIPTOP), aims to give pregnant women in sub-Saharan Africa access to a preventive therapy for malaria known as “intermittent preventive treatment in pregnancy” (IPTp). IPTp is well documented as a method to prevent malaria in pregnancy, specifically using three doses of sulphadoxine-pyrimethamine (SP) to PREVENT malaria during the course of pregnancy.
This five-year TIPTOP project will increase IPTp coverage through local distribution of quality-assured medicine as well as expand antenatal care in the Democratic Republic of Congo, Madagascar, Mozambique, and Nigeria. TIPTOP plans to help local community health workers increase IPTp delivery and make sure that anyone who needs the medicine will have access, which includes reaching out to 400,000 pregnant women and their babies. Data and evidence from this approach will also go toward helping policymakers update their IPTp policies. It is important to note that the WHO currently does recommend that pregnant women in areas of moderate to high transmission of malaria receive IPT, which is detailed in WHO Guidelines.
Nearly half a million people each year died from malaria in 2015, with approximately 90% of all these deaths occurring in Africa (WHO, 2016). Due to reduced immune response, pregnant women are less able to fight off malaria infections and are three times more likely to suffer more serious complications that can lead to death for both mother and baby. Malarial infection during pregnancy can lead to miscarriage, premature birth, low birth weight, congenital infection, and/or death (CDC, 2013).
Unitaid and Jhpiego, an international nonprofit health organization affiliated with the Johns Hopkins University, signed an agreement in early May of this year in support of TIPTOP. Unitaid is investing USD$50 million in the project, while Jhpiego is collaborating with the Barcelona Institute for Global Health, WHO, and Medicines for Malaria Venture to ensure that the desired results and goals are reached. Furthermore, these partnerships reflect ongoing international commitment to the United Nations Development Programme’s Sustainable Development Goal 3: to accelerate maternal and newborn mortality reduction in Sub-Saharan Africa.
Now as a next step, we ask what could be done to lower the costs of the implementation of the E-MOTIVE bundle? The most obvious answer is to consider displacing the tens of thousands of disposable plastic drapes with a purpose-built reusable device.
Fortunately one of the obstetricians involved in the E-MOTIVE study, Dr. Justus Hofmeyr, had been innovating around this very issue, designing a tray with wells that could fit under a woman’s buttocks, collect and accurately measure the. blood. This tray, theMaternaWellTraywas conceived as a device that could be sterilized and reused, and is manufactured in South Africa by Umoya.
The Pumani bubbleCPAP was designed to meet this need for Malawi and is now widely available through Maternova. We had a few questions about post-research phases of the Pumani bubbleCPAP which we posed to Jocelyn Brown, inventor of the Pumani bubbleCPAP, and Molly McCabe, Director of Product Management.